Is GERN a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

2,019 people get GERN articles and Market Currents by email alert.

Get email alerts on GERN »

HEADLINES:

Geron Corporation - Shareholder/Analyst Call
Wed, May 22 • 3 Comments
Position Yourself For Big Returns In The Stem Cell Space: Jason Kolbert
Life Sciences Report • Mon, May 13 • 6 Comments
Geron Management Discusses Q1 2013 Results - Earnings Call Transcript
Fri, Apr 26 • 1 Comment
Stem Cells: Dreamers, Fools, And The Valley Of Death
EnhydrisPECorp • Thu, Apr 25 • 24 Comments
An Industry Outlook With Analyst Vernon Bernardino
Brian Nichols • Mon, Apr 22 • 5 Comments
Companies That Can Mend The Biotech Market: Stephen Brozak
Life Sciences Report • Fri, Apr 12 • 7 Comments
The Future Of Medicine: A Look At 5 Stem Cell Companies
Craig Keolanui • Fri, Mar 22 • 4 Comments
The Stem Cell Revolution Can Jump Start Your Portfolio: Jason Kolbert
Life Sciences Report • Fri, Mar 15 • 16 Comments
Geron Management Discusses Q4 2012 Results - Earnings Call Transcript
Wed, Mar 13 • 2 Comments
2 Stem Cell Research Pioneers And Where They Are Today
Craig Keolanui • Mon, Feb 11 • 9 Comments
Geron: Still Standing
Robert Lawton • Fri, Feb 8 • 246 Comments
Insight On Advanced Cell Technology: An Interview With Gary Rabin, Chairman And CEO
Michael J. Ray • Fri, Feb 8 • 26 Comments
Stephen Brozak: Changing The Way Money Is Made And Diseases Are Cured
Life Sciences Report • Fri, Jan 25 • 3 Comments
Geron Corporation's Recent Catalysts
WM Analyst • Fri, Jan 25 • 2 Comments
2 Speculative Cancer Plays
Bret Jensen • Mon, Jan 21 • 8 Comments
Stem Cells, Dr. Oz And A Potentially Lucrative Investment Opportunity
Charles Moscoe • Wed, Jan 2 • 32 Comments
A Geron Update: Imetelstat Data, Restructuring, And The Road Ahead
PropThink • Tue, Dec 18, 2012 • 4 Comments
Stem Cell Technology To Revolutionize The Skin Care Industry?
Charles Moscoe • Tue, Dec 18, 2012 • 5 Comments
5 Stocks To Watch In Biotech
A John Hodge • Wed, Dec 12, 2012 • 12 Comments
3 Companies With Investment Potential In Targeting Cancer
A John Hodge • Thu, Nov 1, 2012 • 2 Comments

Geron: Still Standing
Robert Lawton • Fri, Feb 8 • 246 Comments

2 Stem Cell Research Pioneers And Where They Are Today
Craig Keolanui • Mon, Feb 11 • 9 Comments
Geron: Still Standing
Robert Lawton • Fri, Feb 8 • 246 Comments
Geron Corporation's Recent Catalysts
WM Analyst • Fri, Jan 25 • 2 Comments
A Geron Update: Imetelstat Data, Restructuring, And The Road Ahead
PropThink • Tue, Dec 18, 2012 • 4 Comments
Geron's Last Chance
Robert Lawton • Wed, Oct 17, 2012 • 584 Comments
Buy Geron: Multiple Catalysts Lie Ahead For This Unique Oncology Company
Helix Investment Research • Thu, Aug 16, 2012 • 25 Comments
Geron Corp: Why I Decided To Take A Flyer On This $2 Biotech Stock
Bret Jensen • Mon, Feb 27, 2012 • 24 Comments
Geron: Mea Culpa
Robert Lawton • Mon, Feb 6, 2012 • 642 Comments
Geron Is Now A Bargain Buy
Jeremy Richards • Tue, Dec 27, 2011 • 16 Comments
Geron Dumps Stem Cells For Cancer Focus
The Burrill Report • Thu, Nov 17, 2011 • 3 Comments
Geron Exits Stem Cells To Focus On Oncology
Henry McCusker • Tue, Nov 15, 2011 • 3 Comments
Geron Reports $19.5M Net Loss In Q3, Says R&D Cost To Rise
Henry McCusker • Tue, Nov 8, 2011 • 4 Comments
Geron Q2 Results: Net Loss of $21.1 Million
Henry McCusker • Mon, Aug 1, 2011
Geron: Investing in the Promise of Stem Cell Technology
Michael J. Ray • Mon, May 23, 2011 • 6 Comments
Just One Stock: The Biopharma Veteran Facing a Landmark Stem Cell Trial
Robert Lawton • Fri, Jan 28, 2011 • 581 Comments
Despite Pipeline Success, Still Too Early to Move on Geron
Zacks Investment Research • Tue, Dec 7, 2010
Geron: Buyer Beware
The Lonely Value Investor • Wed, Oct 13, 2010 • 132 Comments
Geron Explores New Application for Hampered Alzheimer's Drug
The Burrill Report • Mon, Feb 1, 2010 • 3 Comments
Geron: Huge Potential in Oncology, Regenerative Med Pipeline
VFC's Stock House • Tue, Aug 18, 2009 • 2 Comments
Geron's Risk-Reward Profile - Best in Biotech?
Beacon Asset Managers • Fri, Jun 12, 2009 • 14 Comments

Position Yourself For Big Returns In The Stem Cell Space: Jason Kolbert
Life Sciences Report • Mon, May 13 • 6 Comments
Stem Cells: Dreamers, Fools, And The Valley Of Death
EnhydrisPECorp • Thu, Apr 25 • 24 Comments
An Industry Outlook With Analyst Vernon Bernardino
Brian Nichols • Mon, Apr 22 • 5 Comments
Companies That Can Mend The Biotech Market: Stephen Brozak
Life Sciences Report • Fri, Apr 12 • 7 Comments
The Future Of Medicine: A Look At 5 Stem Cell Companies
Craig Keolanui • Fri, Mar 22 • 4 Comments
The Stem Cell Revolution Can Jump Start Your Portfolio: Jason Kolbert
Life Sciences Report • Fri, Mar 15 • 16 Comments
Insight On Advanced Cell Technology: An Interview With Gary Rabin, Chairman And CEO
Michael J. Ray • Fri, Feb 8 • 26 Comments
Stephen Brozak: Changing The Way Money Is Made And Diseases Are Cured
Life Sciences Report • Fri, Jan 25 • 3 Comments
2 Speculative Cancer Plays
Bret Jensen • Mon, Jan 21 • 8 Comments
Stem Cells, Dr. Oz And A Potentially Lucrative Investment Opportunity
Charles Moscoe • Wed, Jan 2 • 32 Comments
Stem Cell Technology To Revolutionize The Skin Care Industry?
Charles Moscoe • Tue, Dec 18, 2012 • 5 Comments
5 Stocks To Watch In Biotech
A John Hodge • Wed, Dec 12, 2012 • 12 Comments
3 Companies With Investment Potential In Targeting Cancer
A John Hodge • Thu, Nov 1, 2012 • 2 Comments
Neuralstem Swinging For The ALS Fences
Richard Richter • Mon, Oct 29, 2012 • 5 Comments
The Potential Giant Killer That Is Advanced Cell Technology
Michael J. Ray • Mon, Oct 8, 2012 • 45 Comments
Mr. Market's Stem Cell Roulette
Brian L. Wilson • Fri, Oct 5, 2012 • 37 Comments
3 Best Biotech Stocks For This Week (Part III)
Jorge Aura • Mon, Sep 24, 2012 • 17 Comments
Why Neuralstem Could Provide A 10x Return
John H. Ford • Tue, Sep 11, 2012 • 28 Comments
Today's Market News To Trade On: 5 Stocks Moving On News
Matthew Smith • Tue, Sep 11, 2012 • 2 Comments
Vivus, Arena: Don't Be Too Late To The Punch Bowl, Buy Other Stocks
Takeover Analyst • Sat, Sep 8, 2012 • 14 Comments

Geron Corporation - Shareholder/Analyst Call
Wed, May 22 • 3 Comments
Geron Management Discusses Q1 2013 Results - Earnings Call Transcript
Fri, Apr 26 • 1 Comment
Geron Management Discusses Q4 2012 Results - Earnings Call Transcript
Wed, Mar 13 • 2 Comments
Geron Management Discusses Q3 2012 Results - Earnings Call Transcript
Tue, Oct 30, 2012 • 1 Comment
Geron's CEO Presents at Update on Imetelstat Clinical Development Program Conference (Transcript)
Mon, Sep 10, 2012 • 4 Comments
Geron Management Discusses Q2 2012 Results - Earnings Call Transcript
Tue, Jul 31, 2012 • 1 Comment
Geron CEO Discusses Q3 2010 Results - Earnings Call Transcript
Sat, Oct 30, 2010 • 2 Comments
Geron Corporation Q2 2010 Earnings Call Transcript
Sat, Jul 31, 2010
Geron Corporation Q1 2010 Earnings Call Transcript
Sun, Jun 13, 2010 • 7 Comments
Geron Corporation Q1 2008 Earnings Call Transcript
Fri, May 30, 2008
Geron Corporation Q4 2007 Earnings Call Transcript
Mon, Mar 17, 2008 • 2 Comments

After-Hours Buzz: INTC, AXP & More

at CNBC.com (Jan 17, 2013)
After Hours: Oracle active, Geron shares fall after hours

at MarketWatch.com (Dec 3, 2012)
After-Hours Buzz: ORCL, GERN & More

at CNBC.com (Dec 3, 2012)
Movers & Shakers: Monday’s biggest gaining and declining stocks

at MarketWatch.com (Sep 10, 2012)
Stocks to Watch: GERN, HPQ, ANR & More

at CNBC.com (Sep 10, 2012)
Stocks to Watch: Stocks to Watch Friday: Splunk, Zumiez, Pandora

at MarketWatch.com (Aug 30, 2012)
Movers & Shakers: Thursday’s biggest gaining and declining stocks

at MarketWatch.com (Aug 30, 2012)
Geron Initiates Phase 2 Trial of GRN1005 in Brain Metastases From Breast Cancer

Business Wire (Dec 12, 2011)
Movers & Shakers: Tuesday’s biggest gaining and declining stocks

at MarketWatch.com (Nov 15, 2011)
Stocks to Watch: Stocks to watch Friday: Global Crossing, Clarcor

at MarketWatch.com (Sep 30, 2011)
Biotech Report: Are stem-cell stocks a good buy?

at MarketWatch.com (Jul 13, 2011)
Biotech Stocks: Amylin and Alkermes shine in drug-stocks trading

at MarketWatch.com (Jul 8, 2011)
Stem-cell stocks rise on artificial-trachea report

at MarketWatch.com (Jul 8, 2011)
Lightning Round: Schlumberger Limited, Geron, Oracle and More...

at CNBC.com (Jun 27, 2011)
Biotech Stocks: Regeneron, Cephalon boost biotech stocks

at MarketWatch.com (May 2, 2011)
Biotech Stocks: StemCells shares climb on spinal injury study

at MarketWatch.com (Mar 14, 2011)
Lightning Round OT: Ashland, Quantum and More

at CNBC.com (Jan 26, 2011)
Movers & Shakers: Tuesday’s biggest gaining and declining stocks

at MarketWatch.com (Dec 7, 2010)
Biotech Stocks: Onyx buoys drug stocks; Geron plunges

at MarketWatch.com (Dec 7, 2010)
After Hours: Biotechs see some action late trade

at MarketWatch.com (Oct 11, 2010)

GERN vs. ETF Alternatives

Company Description

Geron is developing first-in-class biopharmaceuticals for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure and diabetes. The company is advancing an anti-cancer drug and a cancer vaccine that target the enzyme telomerase through multiple... More

Sector: Healthcare

Industry: Biotechnology

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Thursday, May 23, 1:48 PM BioTime (BTX -0.2%) says its shareholders have overwhelmingly approved the planned acquisition of stem cell-related assets from Geron (GERN). The green light was given at a special meeting of shareholders, with at least 32.5M votes coming in favor from the 34.5M shares represented and voted. Comment! [Healthcare, M&A]
Friday, April 26, 10:48 AM Geron (GERN -5%) slips after posting a mixed Q1 report late yesterday that came up short on its bottom line. The company also announced plans to cut its workforce by about a third and discontinue its discovery research and companion diagnostics programs, as the pharmaceutical company plans to put its entire focus on the development of Imetelstat, a treatment for hematologic myeloid malignancies. 1 Comment [Healthcare, On the Move, Earnings]
Thursday, April 25, 5:04 PM Geron (GERN): Q1 EPS loss of $0.09 misses by $0.01. Revenue of $765M beats by $55M. (PR). Comment! [Healthcare, Earnings, Breaking News]
Thursday, April 25, 12:10 AM Notable earnings after Thursday’s close: AEM, ALTR, AMCC, AMKR, AMZN, BIDU, BJRI, BLDR, BMRN, CALX, CAMP, CB, CBG, CENX, CERN, CINF, CLWR, CRUS, CSTR, CTCT, DECK, DLB, ELY, EMN, EXPE, FII, FR, FSL, GERN, IGT, IM, INAP, INFA, KBR, KEG, KLAC, LEG, MCRS, MXIM, N, NR, NTGR, OLN, PFG, PKI, PMCS, QLIK, RMD, RRC, RSG, SBUX, SIMO, SPN, SWKS, SYNA, TCO, THRX, TLAB, UHS, VPRT, VRSN, WRE, WYNN Comment! [Earnings]
Wednesday, April 24, 5:35 PM Notable earnings after Thursday’s close: AEM, ALTR, AMCC, AMKR, AMZN, BIDU, BJRI, BLDR, BMRN, CALX, CAMP, CB, CBG, CENX, CERN, CINF, CLWR, CRUS, CSTR, CTCT, DECK, DLB, ELY, EMN, EXPE, FII, FR, FSL, GERN, IGT, IM, INAP, INFA, KBR, KEG, KLAC, LEG, MCRS, MXIM, N, NR, NTGR, OLN, PFG, PKI, PMCS, QLIK, RMD, RRC, RSG, SBUX, SIMO, SPN, SWKS, SYNA, TCO, THRX, TLAB, UHS, VPRT, VRSN, WRE, WYNN Comment! [Earnings]
Tuesday, April 9, 9:33 AM Geron (GERN -4.3%) looks like it will be unable to use its imetelstat drug for treating lung-cancer patients after final results from a Phase II study confirm that the medicine was ineffective in a sub-group of patients in which initial results had looked promising. (PR) 1 Comment [Healthcare]
Thursday, March 14, 10:49 AM Shares of Geron (GERN -6.1%) get slammed today, despite posting a solid Q4 report after yesterday's close. Revenues soared by nearly 175% from the prior year period, easily topping consensus estimates. However, concerns over an ongoing investigation into lab value abnormalities from its essential thrombocythemia study, plus opaque visibility on imetelstat progress have prompted a number of firms to cut their ratings. Piper Jaffray downgraded the shares to Overweight, while mid-day yesterday Stifel Nicolaus went even further, cutting the shares to sell. Comment! [Healthcare, Earnings, On the Move]
Tuesday, March 12, 5:07 PM Geron (GERN): Q4 EPS of -$0.12 beats by $0.02. Revenue of $689K beats by $189K. (PR) Comment! [Earnings, Breaking News, Healthcare]
Tuesday, March 12, 12:10 AM Notable earnings after Tuesday’s close: DOLE, GERN, HRZN, IRET, KTOS, PPHM, VELT Comment! [Earnings]
Monday, March 11, 5:35 PM Notable earnings after Tuesday’s close: DOLE, GERN, HRZN, IRET, KTOS, PPHM, VELT 2 Comments [Earnings]
Friday, January 18, 9:17 AM Geron (GERN) +5.4% after an upgrade to Buy with $3 price target by Piper Jaffray's Charles Duncan. The current price of $1.66 reflects past challenges, he says, but leaves room for substantial upside over the course of the next year. That Geron and INO are buys at Piper while ZIOT and THLD are Holds does not compute, says Dan Rosenblum. Sell-side games, says TheStreet's Adam Feuerstein. 1 Comment [Healthcare, On the Move]
Friday, January 18, 9:10 AM Premarket gainers: PATH +16%. LIFE +12%. NEWL +8%. RIMM +8%. MS +7%. SNE +7%. GERN +5%.
Losers: FNSR -10%. TSRX -9%. WIT -8%. COF -7%. INTC -6%.
2 Comments [On the Move]
Monday, January 7, 1:15 PM Shares of Geron (GERN +2.5%) snd BioTime (BTX +7.6%) both rise today after BTX agrees to buy the intellectual property, including patents and patent applications, and other assets related to GERN's human embryonic stem cell programs. The financial terms of the deal were in a letter of intent announced back in mid-November. Comment! [Healthcare, M&A, On the Move]
Monday, December 10, 2012, 12:45 PM Midday top 10 gainers: CBMX +37%. UNXL +37%. ACUR +32%. GERN +25%. IN +23%. CLDX +23%. GPRC +20%. TELK +19%. SUMR +17%. EJ +16%.
Midday top 10 Losers: ZGNX -47%. CSFS -25%. MEAD -13%. TCCO -12%. GTIM -11%. SEV -10%. GEO -10%. BLIN -10%. DCTH -9%. NQ -9%. Comment! [On the Move]
Monday, December 10, 2012, 9:34 AM Geron (GERN) soars 15.1% after saying that its imetelstat treatment performed well in Phase II trials of patients with a chronic blood disorder called essential thrombocythemia. Geron designed the trial to provide a proof of concept for the potential use of imetelstat to treat blood cancers. Geron shares were slammed last week after it said it was stopping the development of therapies for brain cancer. (Presentation) 1 Comment [Healthcare]
Monday, December 10, 2012, 9:10 AM Premarket gainers: IN +23%. GERN +17%. NXY +15%. CLDX +10%. STSI +7%. AAV +7%.
Losers: ZGNX -39%. CBMX -18%. DMND -5%. Comment! [On the Move]

Gainz Burger
$GERN- any thoughts on earnings results and data? Looks like they will distribute stock and/ or cash one Biotime deal is completed-
Mar 13, 8:56 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

John Motyka
$GERN: Traces Bloodline back to "the horse 'can do!'" One shot left. Do something upsetting and 'breakthough'. Do this & pull the Upset..jdm
Feb 7, 10:04 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

TruffelPig
Looks like $GERN is getting ready for the BioTech grave yard.
12/4/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

John Motyka
Longshots include ARCI, GERN, MAKO and MITK. Study up and lay your bets down on their futures...jdm
10/27/12
Reply (6)

• !Report Abuse
View all 6 replies
FortSumter: John - I do not. From what I understand MAKO is mainly in the west? Is there anybody else besides ISRG that does what they do?
10/27/12
• !Report Abuse
John Motyka: Sumter: Some big boys working on prototypes, but ISRG first to market. The $ for these systems is in hardware and commissions per procedure.
10/29/12
• !Report Abuse
Add a reply...

140 characters

Asif Suria
BioTime, Inc. Issues Open Letter to Shareholders of Geron Corporation $GERN $BTX http://bit.ly/Ty8eci
10/18/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

John Motyka
das: Better think some more about GERN. This one has been a heartbreaker in the past. I continue to Hold GERN and watch...jdm
10/18/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

das756
Nice move on GERN thinking of improving my stake!!
10/18/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

John Motyka
756; GERN has one uniquely special product left to trial out. Do or die time...jdm
10/3/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

das756
purchase BBRY at $7.60, wondering what is happening with GERN?
10/2/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

John Motyka
Techies: Explain GERN recent chart action. Price appreciation+Volume uptrend+SMA crossing = -50% share value! Didnot see it coming. Why? jdm
9/10/12
Reply (3)

• !Report Abuse
View all 3 replies
John Motyka: Technical analysis is in the eye of the beholder. How could such a promising chart be so empty of predictive value?...jdm
9/12/12
• !Report Abuse
Ocean Man: The old saying is TA works until it doesn't.
9/12/12
• !Report Abuse
Add a reply...

140 characters

LATEST REPLIES

John Motyka
Longshots include ARCI, GERN, MAKO and MITK. Study up and lay your bets down on their futures...jdm
10/27/12
Reply (6)

• !Report Abuse
View all 6 replies
FortSumter: John - I do not. From what I understand MAKO is mainly in the west? Is there anybody else besides ISRG that does what they do?
10/27/12
• !Report Abuse
John Motyka: Sumter: Some big boys working on prototypes, but ISRG first to market. The $ for these systems is in hardware and commissions per procedure.
10/29/12
• !Report Abuse
Add a reply...

140 characters

John Motyka
Techies: Explain GERN recent chart action. Price appreciation+Volume uptrend+SMA crossing = -50% share value! Didnot see it coming. Why? jdm
9/10/12
Reply (3)

• !Report Abuse
View all 3 replies
John Motyka: Technical analysis is in the eye of the beholder. How could such a promising chart be so empty of predictive value?...jdm
9/12/12
• !Report Abuse
Ocean Man: The old saying is TA works until it doesn't.
9/12/12
• !Report Abuse
Add a reply...

140 characters

iadops40
GERN also reporting disapointing phase 2 study of imetelstat, shares down -48% pre-market http://seekingalpha.com/n/bci5
9/10/12
Reply (1)

• !Report Abuse
View all 1 replies
Gainz Burger: OUCH! was the recent run just a pump n dump?
9/10/12
• !Report Abuse
Add a reply...

140 characters

TruffelPig
GERN has left my portfolio.....so sick of this company.....sold with loss. Bought EXEL.
8/9/12
Reply (3)

• !Report Abuse
View all 3 replies
TruffelPig: Not sure - GERN had a hug he run up but EXEL is probably better anyhow.
9/9/12
• !Report Abuse
TruffelPig: EXEL will have a product soon on the market - GERN after xxxxxxxxx years Phase II again.........
9/9/12
• !Report Abuse
Add a reply...

140 characters

John Motyka
GERN followers: Something is afoot...jdm
8/28/12
Reply (8)

• !Report Abuse
View all 8 replies
Ocean Man: Something afoot means something happening, something amiss means something not right.
8/28/12
• !Report Abuse
John Motyka: GERN: Price action last 6-8wks suggests "Sugar Daddy" w/ private money is providing downside support level. Cancer Tx may be in the news.jdm
8/29/12
• !Report Abuse
Add a reply...

140 characters

iadops40
Huge all-star biotech conference (Rodman & Renshaw) in New York Sept. 9-11 CLSN GALE GERN IBIO INO KERX NVAX NBS ONTY VVUS
8/28/12
Reply (2)

• !Report Abuse
View all 2 replies
iadops40: http://bit.ly/RntWCr
8/28/12
• !Report Abuse
DAG1996: thanks for sharing that.
8/28/12
• !Report Abuse
Add a reply...

140 characters

iadops40
Huge all-star biotech conference (Rodman & Renshaw) in New York Sept. 9-11 CLSN GALE GERN IBIO INO KERX NVAX NBS ONTY VVUS
8/27/12
Reply (1)

• !Report Abuse
View all 1 replies
iadops40: http://bit.ly/RntWCr
8/27/12
• !Report Abuse
Add a reply...

140 characters

TruffelPig
GERN makes another run today.
6/27/12
Reply (4)

• !Report Abuse
View all 4 replies
TruffelPig: Second half of this year should bring catalysts; let us hope in a good way
6/27/12
• !Report Abuse
Gainz Burger: Im with you TP- have owned GERN for years now and am underwater. Pipeline is extensive & they are a good takeover candidate from big Pharma
6/27/12
• !Report Abuse
Add a reply...

140 characters

John Motyka
GERN: Beats but still bleeds out. Patents and Phase III trail will tell the tale's outcome. Soon I hope. Nice entry point. Hold & Hope...jdm
5/4/12
Reply (6)

• !Report Abuse
View all 6 replies
TruffelPig: I think my posts are delayed.......
6/25/12
• !Report Abuse
John Motyka: GERN found a 'Sugar Daddy'. Could be frontrunner to next quarterly progress report. These new Cancer Tx's better be plenty Good...jdm
6/25/12
• !Report Abuse
Add a reply...

140 characters

TruffelPig
Any news on GERN? 13% up, no gap
6/22/12
Reply (8)

• !Report Abuse
View all 8 replies
John Motyka: One huge Block of Shares, you report? GERN found Sugar Daddy!!!!...jdm
6/23/12
• !Report Abuse
John Motyka: X7 Volume holds onto gains. Hedge guy or Private Monies or Banker or Believer in GERN coming back to play. I Hold and Wait for GERN...jdm
6/23/12
• !Report Abuse
Add a reply...

140 characters

John Motyka
All~GERN wins patent for Cancer Treatment. ...jdm
4/10/12
Reply (3)

• !Report Abuse
View all 3 replies
John Motyka: Funk~ This could be the beginning of a feeding frenzy. Let's watch developments together and keep in touch...jdm
4/10/12
• !Report Abuse
Funkengruven: I'm ready for "Mr. Toads Wild Ride"...
4/11/12
• !Report Abuse
Add a reply...

140 characters

John Motyka
DAG~Very quite. Earnings report for GERN 03/07/12. Beat est but still bleeding out. Firestorm ahead for Phase III. I continue to Hold...jdm
3/29/12
Reply (18)

• !Report Abuse
View all 18 replies
DAG1996: thanks John. and no worries about earlier mistake.
4/3/12
• !Report Abuse
John Motyka: DAG~ You are always welcome here...jdm
4/3/12
• !Report Abuse
Add a reply...

140 characters

DAG1996
GERN anyone know of any upcoming catalysts? i want to sell out, but not if there's a near-term catalyst.
3/29/12
Reply (14)

• !Report Abuse
View all 14 replies
DAG1996: lol no way in heck i'd buy a tiny biotech priced higher than most of the major pharmas. $50 is a sell price for a biotech, not a buy.
3/29/12
• !Report Abuse
John Rayhall: Ya def that would be insane to buy there.
3/29/12
• !Report Abuse
Add a reply...

140 characters

Funkengruven
GERN... incredible trading volume!
2/28/12
Reply (1)

• !Report Abuse
View all 1 replies
Funkengruven: OPTT also! Good for me, I need the balance!
2/28/12
• !Report Abuse
Add a reply...

140 characters

John Motyka
Noreika: How now? ALU, GERN or ARCI? What say you these days?...jdm
2/18/12
Reply (3)

• !Report Abuse
View all 3 replies
Noreika: ..but I should buy into either GERN or ALU if not too late.
2/20/12
• !Report Abuse
John Motyka: Noreika: SA has some articles about ARCI. Recycling patents, contracts w/ electric and actual earnings. Sharks circling on GERN & ALU...jdm
2/21/12
• !Report Abuse
Add a reply...

140 characters

GERN Geron Corporation

GERN

Geron Corporation